RxDoctor Payments DataLook up a doctor →

Mark Kachadurian, DO

Neurology · Farmington Hills, MINPI 1376540286

Payments from drug & device makers

$257,830in general payments, 2019–2025

Across 1,681 payments — averaging $153.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$97K
  • AbbVie$73K
  • Amgen$45K
  • Teva Pharmaceuticals USA, Inc.$14K
  • Biohaven Pharmaceuticals, Inc.$9K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$11,6885%
  • Speaking & faculty fees$208,27281%
  • Grants$1290%
  • Travel & lodging$9,2984%
  • Food & beverage$28,18711%
  • Education$2560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC242$96,612
AbbVie(2 entities)216$73,196
Amgen(2 entities)107$44,998
Teva Pharmaceuticals USA, Inc.95$14,128
Biohaven Pharmaceuticals, Inc.31$9,431
Biohaven Pharmaceutical Holding Company Ltd.11$2,875
Novartis285$2,615
UCB, Inc.63$1,537
Biogen44$966
Bristol Myers Squibb74$964
Neurocrine Biosciences, Inc.38$904
Lundbeck LLC29$802
Pfizer39$746
EMD Serono, Inc.47$746
Sanofi32$595
AstraZeneca(2 entities)25$517
Eisai Inc.14$458
CSL Behring20$393
Alnylam Pharmaceuticals Inc.23$392
Takeda Pharmaceuticals U.S.A., Inc.13$341
Sumitomo Pharma America, Inc.21$341
Catalyst Pharmaceuticals, Inc.10$319
Acadia Pharmaceuticals Inc16$302
Johnson & Johnson(2 entities)14$297
MDD US Operations, LLC14$228
Neurelis, Inc.14$225
Adamas Pharmaceuticals, Inc.11$203
SK Life Science, Inc.6$185
TG Therapeutics, Inc.7$157
Genentech USA, Inc.8$146
Merz Pharmaceuticals, LLC4$141
Kyowa Kirin, Inc.7$137
Impel Pharmaceuticals Inc.7$120
Grifols USA, LLC5$116
Sunovion Pharmaceuticals Inc.8$113
Supernus Pharmaceuticals, Inc.7$108
Vanda Pharmaceuticals Inc.4$103
Axsome Therapeutics, Inc.3$101
Jazz Pharmaceuticals Inc.6$100
Avanir Pharmaceuticals, Inc.4$77
Livanova USA, Inc.3$71
Otsuka America Pharmaceutical, Inc.3$69
Amneal Pharmaceuticals LLC3$68
Cala Health, Inc.4$67
Argenx US, Inc.3$64
Acorda Therapeutics, Inc3$62
Akcea Therapeutics, Inc.3$62
Banner Life Sciences, LLC4$59
Mallinckrodt Hospital Products Inc.2$52
Zogenix Inc.3$50
Corium, LLC2$50
Strongbridge US Inc.3$42
E.r. Squibb & Sons, L.L.C.2$41
Bausch Health US, LLC2$40
Greenwich Biosciences, Inc.2$39
Aucta Pharmaceuticals, Inc.3$36
Assertio Therapeutics, Inc.2$33
ANI Pharmaceuticals, Inc.1$27
Cordis US CORP.1$25
Xeris Pharmaceuticals, Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$257,830 in reported general payments places this provider in the 90th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$296,576
Medicare patients
448
Services billed
10,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5018$961,906
CopaxoneGlatiramer Acetate67$433,720
Teriflunomide29$68,883
UbrelvyUbrogepant44$66,545
Aimovig AutoinjectorErenumab-Aooe66$62,498
Glatiramer Acetate30$60,363
Emgality PenGalcanezumab-Gnlm76$58,102
Nurtec OdtRimegepant Sulfate36$49,706
VimpatLacosamide16$34,984
QuliptaAtogepant33$34,108
Emgality SyringeGalcanezumab-Gnlm24$19,266
FycompaPerampanel11$12,209
Lamotrigine ErLamotrigine18$10,457
Ropinirole ErRopinirole Hcl47$9,904
Rasagiline Mesylate51$9,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$14,128$433,72067 claims
AbbVieUbrelvy, Qulipta$73,196$100,65377 claims
PfizerNurtec Odt, Dilantin$746$51,66753 claims
UCB, Inc.Vimpat$1,537$34,98416 claims
Eisai Inc.Fycompa$458$12,20911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 neurology providers in Michigan.

Other neurology in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →